首页> 外文OA文献 >Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study

【2h】

Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study

机译：二线和第三线化疗的生存分析与Irinotecan之后是Topotecan或Topotecan，然后是Irinotecan进行广泛的小型细胞肺癌患者：单中心回顾性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
gokmen aktas; Kuş Tulay; mehmet emin kalender; alper sevinc; celaletdin camci; seval kul;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study [J] . Gokmen Aktas, Tulay Kus, Mehmet Emin Kalender, OncoTargets and therapy . 2016,第2期

机译：单中心回顾性研究：伊立替康，托泊替康或托泊替康，伊立替康二线和三线化疗对广泛期小细胞肺癌患者的生存分析：单中心回顾性研究
2. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial [J] . Goto Koichi, Ohe Yuichiro, Shibata Taro, The lancet oncology . 2016,第8期

机译：联合化疗联合顺铂，依托泊苷和伊立替康与伊泊替康相比单独使用拓扑替康作为敏感性复发小细胞肺癌患者的二线治疗（JCOG0605）：一项多中心，开放标签，随机3期试验
3. E5501: Phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer [J] . OwonikokoT.K., AisnerJ., WangX.V., Cancer chemotherapy and pharmacology. . 2014,第1期

机译：E5501：依托泊苷/顺铂测序的拓扑替康和依托泊苷测序的伊立替康/顺铂用于广泛期小细胞肺癌的II期研究
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. Patient Derived Xenograft Models of Small-cell Lung Cancer Provide Molecular Insights into Mechanisms of Chemotherapy Cross-resistance [D] . Myers, David T. 2018

机译：小细胞肺癌的患者衍生异种移植模型为化学疗法交叉耐药机制提供分子见解
6. Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study [O] . Gokmen Aktas, Tulay Kus, Mehmet Emin Kalender, 2016

机译：单中心回顾性研究：伊立替康托泊替康或托泊替康伊立替康二线和三线化疗对广泛期小细胞肺癌患者的生存分析：单中心回顾性研究
7. Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis [O] . Yuan Zhao, Bing Wan, Tianli Zhang, 2019

机译：Irinotecan，Topotecan，Paclitaxel或Docetax用于小细胞肺癌的二线治疗：单中心回顾性研究效率比较和预后分析

Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study

著录项

引文网络

相似文献

相关主题

期刊订阅